Low-Dose Aspirin

Low-dose aspirin (75-100mg daily) represents one of the most extensively studied pharmaceutical interventions for longevity and healthspan extension. Research indicates that regular low-dose aspirin use significantly reduces the risk of major cardiovascular events, including heart attack and ischemic stroke, particularly in individuals with existing cardiovascular risk factors. Large-scale trials involving hundreds of thousands of participants have demonstrated that aspirin's anti-platelet effects can reduce cardiovascular mortality by 10-20% in appropriate populations.

Beyond cardiovascular protection, studies suggest that long-term aspirin use may reduce the incidence of certain cancers, particularly colorectal cancer, with effects becoming apparent after 5-10 years of consistent use. The mechanism appears to involve both anti-inflammatory pathways and potential effects on cellular proliferation and apoptosis. However, these benefits must be weighed against increased risks of major bleeding, particularly gastrointestinal and intracranial hemorrhage, which rise with age and concurrent medication use.

Research indicates that the risk-benefit profile of low-dose aspirin varies significantly based on individual factors including age, cardiovascular risk, bleeding risk, and overall health status. While widely available over-the-counter, the decision to use low-dose aspirin for prevention should involve careful consideration of personal risk factors, as the potential for serious bleeding complications means it may not be appropriate for all individuals seeking longevity interventions.